cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.35003/7wowqi/tkuo48
title: asteroid_05km16Tr_noA.inp

description: :unav
DOI: 10.35003/7wowqi/czevgt
title: asteroid_1km16Tr_noA.inp

description: :unav
DOI: 10.35003/7wowqi/pvttyt
title: asteroid_01km16Tr_noA.inp

description: :unav
DOI: 10.35003/7wowqi/dihcpg
title: asteroid_3km18v.inp

description: :unav
DOI: 10.35003/7wowqi/bk41rz
title: asteroid_01km18v_noA.inp

description: :unav
DOI: 10.35003/7wowqi/crnose
title: asteroid_3km16Tr.inp

description: :unav
DOI: 10.35003/7wowqi/kvdyru
title: asteroid_2km18v.inp

description: :unav
DOI: 10.35003/7wowqi/wldfzi
title: 2022je007264-sup-0001-supporting information si-s01.docx

description: supplement
DOI: 10.35003/7wowqi/ime9ug
title: 10.1029-2022JE007264Figure219630003.pptx

description: :unav
DOI: 10.35003/7wowqi/b89z0z
title: 10.1029-2022JE007264Figure219630007.pptx

description: :unav
DOI: 10.35003/7wowqi/xlzffo
title: 10.1029-2022JE007264Figure219630004.pptx

description: :unav
DOI: 10.35003/7wowqi/0qeywn
title: 10.1029-2022JE007264Figure219630005.pptx

description: :unav
DOI: 10.35003/7wowqi/fm0g8q
title: 10.1029-2022JE007264Figure219630006.pptx

description: :unav
DOI: 10.35003/7wowqi/hg6gvf
title: 10.1029-2022JE007264Figure219630002.pptx

description: :unav
DOI: 10.35003/7wowqi/jllkyj
title: 10.1029-2022JE007264Figure219630001.pptx

description: :unav
DOI: 10.35003/nxhbee
title: Replication Data for: Crustal Porosity of Lunar Impact Basins

description: • The bulk density and porosity of the upper highland crust are revisited using a high-resolution GRAIL gravity field model (Park et al., 2015) in combination with LOLA topography (Smith et al., 2017) and independently estimated grain densities • Using the estimated bulk densities in combination with grain densities estimated from surface composition, the porosity of the upper crust was determined. Each grid point with a spacing of 0.75 deg was calculated using a circular analysis region of 3 deg radius. The grids are equally sampled following the sample theorem of Driscoll and Healy (1994). • For many impact basins, porosity is reduced within their peak ring and increased near and just exterior to the main rim • Large impact basins show a stronger pronounced porosity signature than smaller basins, and old impact basins reveal a muted porosity signature compared to younger basins
DOI: 10.35003/nxhbee/iwnroe
title: bulk_density.txt

description: The ascii file has the following format: column 1: co-latitude in deg column 2: longitude in deg column 3: bulk density in kg/m³
DOI: 10.35003/nxhbee/9pc7fz
title: porosity.txt

description: The ascii file has the following format: column 1: co-latitude in deg column 2: longitude in deg column 3: porosity in %
DOI: 10.34740/kaggle/dsv/5632977
title: YouTube Trending Video Dataset (updated daily)
DOI: 10.4121/21740075
title: Data and images for 'Milk, mylk or drink: Do packaging cues affect consumers’ understanding of plant-based products?'

description: We created and tested 9 images of packages of plant-based milk and 9 images of plant-based chicken meat varying the “animalness” of terminology, container, image, and verbal claim. An online survey was answered by a sample of 600 participants from the US population. We assessed the willingness to try the product, the perceived origin of the product (vegetable -animal), the time to give the answer to the origin question, and the sensory expectations for the product.<br>
DOI: 10.4121/21740075.v1
title: Data and images for 'Milk, mylk or drink: Do packaging cues affect consumers’ understanding of plant-based products?'

description: We created and tested 9 images of packages of plant-based milk and 9 images of plant-based chicken meat varying the “animalness” of terminology, container, image, and verbal claim. An online survey was answered by a sample of 600 participants from the US population. We assessed the willingness to try the product, the perceived origin of the product (vegetable -animal), the time to give the answer to the origin question, and the sensory expectations for the product.<br>
DOI: 10.22008/fk2/v9ahqn
title: Geological map of the south-east coast of Nuussuaq between Ataata Kuua and Saqqaqdalen, central West Greenland, 1: 50 0000, with detailed sections

description: Geologisk kort over Grønland / Geological map of Greenland - 1:50 000, central West Greenland, Nuussuaq
DOI: 10.22008/fk2/qgcrjp
title: Geological section along the south coast of Disko, central West Greenland. 1:20 000 coloured geological sheet.

description: Geological cross section
DOI: 10.5281/zenodo.7907756
title: An orally angiotensin - (1 – 7) inclusion compound reduce time to reaction in 2 stroop task and modify heart rate variability after continuous test in mountain 3 bike cyclists

description: data for An orally angiotensin - (1 – 7) inclusion compound reduce time to reaction in 2 stroop task and modify heart rate variability after continuous test in mountain 3 bike cyclists,<br> Recently our group showed that hydroxypropyl β-cyclodextrin (HPβ-CD)-Angiotensin-(1-7) (HPβ-CD-Ang-[1-7]) oral formulation affects performance and decreases the perceived effort of mountain bike (MTB) athletes. Twenty-one male MTB practitioners were divided into a continuous protocol time trial and repeated sprint groups. Three hours before a 20-km cycling time trial or 4×30-s repeated all-out sprints on a leg cycle ergometer, the athletes received HPβ-CD-Ang-(1-7) (0.8 mg) or HPβ-CD-placebo (only HPβ-CD) oral capsules over a 7-day interval randomized crossover design. At rest and immediately after the exercise protocol, the ratings of perceived recovery and the visual analog scale were assessed, and the volunteers completed the Stroop task (ST). Heart rate variability was measured at rest and peak effort. There were no differences in the perceived variables. The ST showed that HPβ-CD-Ang-(1-7) supplementation reduced the reaction time (rest 1032±331 ms vs. after protocol 902±286 ms, p=0.05) after the continuous time trial. The withdrawal of the parasympathetic components in the peak effort to the continuous protocol was not different from that of rest in the HPβ-CD-Ang-(1-7) condition. The results are pioneering, especially in humans, but indicate that Angiotensin-(1-7) potentially affects reaction time and the parasympathetic withdrawal after continuous protocol time trial.
DOI: 10.5281/zenodo.7907755
title: An orally angiotensin - (1 – 7) inclusion compound reduce time to reaction in 2 stroop task and modify heart rate variability after continuous test in mountain 3 bike cyclists

description: data for An orally angiotensin - (1 – 7) inclusion compound reduce time to reaction in 2 stroop task and modify heart rate variability after continuous test in mountain 3 bike cyclists,<br> Recently our group showed that hydroxypropyl β-cyclodextrin (HPβ-CD)-Angiotensin-(1-7) (HPβ-CD-Ang-[1-7]) oral formulation affects performance and decreases the perceived effort of mountain bike (MTB) athletes. Twenty-one male MTB practitioners were divided into a continuous protocol time trial and repeated sprint groups. Three hours before a 20-km cycling time trial or 4×30-s repeated all-out sprints on a leg cycle ergometer, the athletes received HPβ-CD-Ang-(1-7) (0.8 mg) or HPβ-CD-placebo (only HPβ-CD) oral capsules over a 7-day interval randomized crossover design. At rest and immediately after the exercise protocol, the ratings of perceived recovery and the visual analog scale were assessed, and the volunteers completed the Stroop task (ST). Heart rate variability was measured at rest and peak effort. There were no differences in the perceived variables. The ST showed that HPβ-CD-Ang-(1-7) supplementation reduced the reaction time (rest 1032±331 ms vs. after protocol 902±286 ms, p=0.05) after the continuous time trial. The withdrawal of the parasympathetic components in the peak effort to the continuous protocol was not different from that of rest in the HPβ-CD-Ang-(1-7) condition. The results are pioneering, especially in humans, but indicate that Angiotensin-(1-7) potentially affects reaction time and the parasympathetic withdrawal after continuous protocol time trial.
DOI: 10.6073/pasta/4c74a4919364fd27ea1c64916c339c36
title: Leaf Area Index at Harvard Forest HEM and LPH Towers since 1998

description: Leaf area index (LAI) measurements are made to detect changes in forest leaf area that are important in understanding forests’ carbon dioxide (CO2) uptake and water use. Measurements of LAI in different forest types are useful understanding differences between forests in CO2 uptake and water use, while variation in LAI in the same forest type over time helps to explain interannual variation and long-term trends in carbon storage and water use. Within a single year, especially for deciduous forests, seasonal changes in LAI are very important in determining the forest’s cycle of CO2 uptake and water use. LAI measurements at Harvard Forest were begun in the old-growth hemlock stand in 1998 in order to understand and develop a predictive model for its carbon exchange, and were begun at the Little Prospect Hill site in 2002 to better understand CO2 uptake and carbon storage at this site, which were measured by the eddy-covariance method beginning in 2002. Due to a lack of personnel, multiple annual measurements of LAI to examine seasonal change in leaf area did not begin until 2007.
DOI: 10.22008/fk2/ecxcql
title: Geologisk kort over Grønland, 1:100 000, Agto 67 V.1 Nord

description: Geologisk kort over Grønland / Geological map of Greenland - 1:100 000, central West Greenland, Nassuttooq/Nordre Strømfjord
DOI: 10.5281/zenodo.7890700
title: Modeling hydraulic heads with impulse response functions in different environmental settings (dataset and code supplement)

description: These folders contain the input data, the scripts, and the output to reproduce the results and figures of Jemeljanova et al. "Modeling hydraulic heads with impulse response functions in different environmental settings".<br> This research is funded by the Latvian Council of Science, project “Spatial and temporal prediction of groundwater drought with mixed models for multilayer sedimentary basin under climate change”, project No. lzp-2019/1-0165 and PostDoc research project agreement No. 1.1.1.2/VIAA/3/19/524.
DOI: 10.5281/zenodo.7890699
title: Modeling hydraulic heads with impulse response functions in different environmental settings (dataset and code supplement)

description: These folders contain the input data, the scripts, and the output to reproduce the results and figures of Jemeljanova et al. "Modeling hydraulic heads with impulse response functions in different environmental settings".<br> This research is funded by the Latvian Council of Science, project “Spatial and temporal prediction of groundwater drought with mixed models for multilayer sedimentary basin under climate change”, project No. lzp-2019/1-0165 and PostDoc research project agreement No. 1.1.1.2/VIAA/3/19/524.
DOI: 10.22008/fk2/zy5wbs
title: Geological section along the north coast of Nuussuaq, central West Greenland. 1:20 000 coloured geological sheet.

description: Geological cross section
DOI: 10.48425/351ngp42
title: V_redfox_carcass_examination

description: Red fox carcass examination and dissection data. The data is organized as one file per hunting year (From 1 June to 31 May in the following year) and a readme file with additional information. This dataset contains information about reproductive status, body condition and age of each examined individual, as well as the locations where each fox was shot.
DOI: 10.22008/fk2/fjj3mg
title: Geological section along the north side of the Aaffarsuaq valley and central Nuussuaq, central West Greenland. 1:20 000 coloured geological sheet.

description: Geological cross section
DOI: 10.22008/fk2/audf7k
title: Geological section along the south coast of Nuussuaq, central West Greenland

description: Geological cross section, 1:20 000
DOI: 10.22008/fk2/dhk9y8
title: Geologisk kort over Grønland, 1:100 000, Nigerdlikasik 62 V.2 Syd

description: Geologisk kort over Grønland / Geological map of Greenland - 1:100 000, South-West Greenland, Nunatarsuaq
DOI: 10.6084/m9.figshare.22779068
title: Untitled Item

description: Demo
DOI: 10.6084/m9.figshare.22779068.v1
title: Untitled Item

description: Demo
DOI: 10.25934/pr00005581.11
title: Available IPD datapackage for study 'A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer'

description: This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. The results of Cohort 1 are reported separately (NCT02951767). Cohort 2 (reported here) will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen. Participants in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.
DOI: 10.22008/fk2/oc5wns
title: Geological reconaissance map of the country between latitudes 69­°N and 63°45N, West Greenland

description: Geological map, West Greenland
DOI: 10.25934/pr00005804.10
title: Available IPD datapackage for study 'A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer'

description: This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 (reported here) will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen. The results of the second cohort are reported separately (NCT02108652). Participants in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.
DOI: 10.22008/fk2/sdhft3
title: Geological section across north central Disko from Nordfjord to Pingu, central West Greenland. 1:20 000 coloured geological sheet.

description: Geological cross section
DOI: 10.6084/m9.figshare.22779062
title: Civic and political volunteering

description: Cross-national survey data attached to Civic and Political Volunteering paper published in Journal of Information Technology & Politics
DOI: 10.6084/m9.figshare.22779080
title: Student Health Survey - Form Responses 1 (2).csv

description: Student health data was collected from all over the university via survey, there are 18 features in the dataset.
DOI: 10.25934/pr00006051.17
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer'

description: This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).
DOI: 10.48425/0v4f0b95
title: V_redfox_carcass_examination

description: Red fox carcass examination and dissection data. The data is organized as one file per hunting year (From 1 June to 31 May in the following year) and a readme file with additional information. This dataset contains information about reproductive status, body condition and age of each examined individual, as well as the locations where each fox was shot.
DOI: 10.34740/kaggle/dsv/5633096
title: Student Health Dataset
DOI: 10.17909/bn0s-2879
title: A2744-OD_NIRSpecIFU
DOI: 10.7488/ds/3853
title: Contaminant Removal from Nature’s Self-Cleaning Surfaces

description: This dataset contains molecular dynamics LAMMPS set-up files for simulating droplets removing contamination particles on highly wetting surfaces, such as those on nature's cicada wings or lotus leaves. It relates to the article Sreehari Perumanath, Rohit Pillai and Matthew K. Borg (2023). "Contaminant Removal from Nature’s Self-Cleaning Surfaces". Nano Letters (accepted).
DOI: 10.48425/a1uk2c7k
title: V_redfox_hunting

description: Hunting records of red foxes in Varanger and Finnmarksvidda. The data are organized in two series of files: V_redfox_hunting_YEAR.txt contains all the foxes shot by local hunters in Varanger, and V_redfox_culled_sno_YEAR.txt lists the number of foxes culled by SNO in Varanger and Finnmarksvidda each year. There are two files for each hunting year (From 1 June to 31 May in the following year) and a readme file with additional information. This dataset should be used to represent the dynamics of the numbers of foxes shot.
DOI: 10.5519/qd.m4hatapb
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1001 records)
DOI: 10.25934/pr00005598.13
title: Available IPD datapackage for study 'A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy'

description: This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.
DOI: 10.3886/e188604
title: ECIN Replication Package for "Adverse Selection in the Group Life Insurance Market"

description: These files contain code and the publicly available data used for the study titled "Adverse Selection in the Group Life Insurance Market." Abstract for the study: <br><br>The employer-sponsored life insurance (ESLI) market is particularly susceptible to adverse selection due to community-rated premiums, guaranteed issue coverage, and the existence of a well-functioning individual market as a substitute. Using administrative payroll and healthcare claims data from a large university, we find evidence of adverse selection in the supplemental ESLI market. Employees in worse health, as measured by the Charlson's Comorbidity Index, are more likely to elect coverage than those in better health. Nonetheless, we also find that employees typically do not increase coverage following diagnosis of a severe illness even when they can without providing evidence of insurability. Furthermore, demand estimation shows that employees are not price-sensitive and that the estimated increases in premiums due to adverse selection are unlikely to cause significant welfare loss.<br>
DOI: 10.3886/e188604v1
title: ECIN Replication Package for "Adverse Selection in the Group Life Insurance Market"

description: These files contain code and the publicly available data used for the study titled "Adverse Selection in the Group Life Insurance Market." Abstract for the study: <br><br>The employer-sponsored life insurance (ESLI) market is particularly susceptible to adverse selection due to community-rated premiums, guaranteed issue coverage, and the existence of a well-functioning individual market as a substitute. Using administrative payroll and healthcare claims data from a large university, we find evidence of adverse selection in the supplemental ESLI market. Employees in worse health, as measured by the Charlson's Comorbidity Index, are more likely to elect coverage than those in better health. Nonetheless, we also find that employees typically do not increase coverage following diagnosis of a severe illness even when they can without providing evidence of insurability. Furthermore, demand estimation shows that employees are not price-sensitive and that the estimated increases in premiums due to adverse selection are unlikely to cause significant welfare loss.<br>
DOI: 10.3886/e188604v2
title: ECIN Replication Package for "Adverse Selection in the Group Life Insurance Market"

description: These files contain code and the publicly available data used for the study titled "Adverse Selection in the Group Life Insurance Market." Abstract for the study: <br><br>The employer-sponsored life insurance (ESLI) market is particularly susceptible to adverse selection due to community-rated premiums, guaranteed issue coverage, and the existence of a well-functioning individual market as a substitute. Using administrative payroll and healthcare claims data from a large university, we find evidence of adverse selection in the supplemental ESLI market. Employees in worse health, as measured by the Charlson's Comorbidity Index, are more likely to elect coverage than those in better health. Nonetheless, we also find that employees typically do not increase coverage following diagnosis of a severe illness even when they can without providing evidence of insurability. Furthermore, demand estimation shows that employees are not price-sensitive and that the estimated increases in premiums due to adverse selection are unlikely to cause significant welfare loss.<br>
DOI: 10.3886/e188604v3
title: ECIN Replication Package for "Adverse Selection in the Group Life Insurance Market"

description: These files contain code and the publicly available data used for the study titled "Adverse Selection in the Group Life Insurance Market." Abstract for the study: <br><br>The employer-sponsored life insurance (ESLI) market is particularly susceptible to adverse selection due to community-rated premiums, guaranteed issue coverage, and the existence of a well-functioning individual market as a substitute. Using administrative payroll and healthcare claims data from a large university, we find evidence of adverse selection in the supplemental ESLI market. Employees in worse health, as measured by the Charlson's Comorbidity Index, are more likely to elect coverage than those in better health. Nonetheless, we also find that employees typically do not increase coverage following diagnosis of a severe illness even when they can without providing evidence of insurability. Furthermore, demand estimation shows that employees are not price-sensitive and that the estimated increases in premiums due to adverse selection are unlikely to cause significant welfare loss.<br>